|
|
Post by hansgruber on Jan 22, 2016 14:11:35 GMT
The fat lady is warming up. The bright side of this is that there's no way asstellus is walking away at this point if they're this close. Worse case 8.50. i give it a 0.001% chance that they need to raise their offer or anbetter bid comes in. It looks like the billionaire savior gabelli wasn't the savior for shareholders everyone thought he was. Just working for asstellus to buy a bunch of shares and tender them for arbitage. Game over. I will be selling once this hits 8.50 in a few weeks once they announce they've got the shares they need in 3 weeks.
|
|
jak
Junior Member
Pic reflects current mood
Posts: 88 
|
Post by jak on Jan 22, 2016 15:01:19 GMT
money.cnn.com/news/newsfeeds/articles/prnewswire/CG05082.htm Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics PR Newswire - ASTELLAS IS COMMITTED TO TRANSACTION, ACQUISITION OF OCATA IS A STRATEGIC PRIORITY - January 22, 2016: 08:52 AM ET TOKYO and Massachusetts, Jan. 22, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata") today announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of US$8.50 per share, net to the holder in cash ("Tender Offer") until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The Tender Offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the Tender Offer will allow Ocata's stockholders additional time to tender their shares into the Tender Offer. Astellas is a pharmaceutical company dedicated to improving the health of people around the world. All terms and conditions of the Tender Offer shall remain unchanged during the extended offering period. "We remain very excited about the combination of Astellas and Ocata and are fully committed to achieving a successful completion of the transaction," commented Yoshihiko Hatanaka, President and CEO, Astellas. "We highly value Ocata's R&D capabilities, where we plan to make further investments, and expect Ocata to take a key role within Astellas' R&D in ophthalmology and cell therapy. We believe that Astellas' offer represents an attractive proposal to Ocata's shareholders, and we look forward to closing the tender offer at the end of this offering period." About Astellas Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en. About Ocata Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Ocata's most advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata's intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information on Ocata, please visit www.ocata.com. Cautionary Statement Regarding Forward-Looking Statements Any statements made in this communication that are not statements of historical fact, including statements about the expected timetable for completing the transaction and Astellas' and Ocata's beliefs and expectations and statements about Astellas' proposed acquisition of Ocata, including the timing of and closing conditions to the acquisition, and the potential effects of the acquisition on both Astellas and Ocata are forward-looking statements that are based on management's beliefs, certain assumptions and current expectations and should be evaluated as such. These statements may be identified by their use of forward-looking terminology such as the words "expects," "projects," "anticipates," "intends" and other similar words. Forward-looking statements include statements that may relate to Astellas' or Ocata's plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, general economic, business and market conditions and the satisfaction of the conditions to closing of the proposed transaction. For a more complete discussion of certain of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements with respect to Ocata, see the discussion of risks and uncertainties in Ocata's annual report on Form 10-K for the fiscal year ended December 31, 2014, its most recent Quarterly Report on Form 10-Q, and other SEC filings. The forward-looking statements contained in this news release are made as of the date hereof, and neither Astellas nor Ocata undertakes any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law. Important Additional Information This communication is provided for informational purposes only. No statement in this document is an offer to purchase or a solicitation of an offer to sell securities. Any offers to purchase or solicitation of offers to sell will be made only pursuant to the Tender Offer Statement on Schedule TO (including the Offer to Purchase, the Letter of Transmittal and other documents relating to the Offer) that Astellas and Laurel, an indirect wholly-owned subsidiary of Astellas, filed with the Securities and Exchange Commission (the "SEC") on November 19, 2015. In addition, Ocata filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Tender Offer on November 19, 2015. THE TENDER OFFER STATEMENT (INCLUDING THE OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY OCATA'S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Such documents have been made available to Ocata's stockholders at no expense to them. In addition, you may obtain copies of these documents (and all other Offer documents filed with the SEC) at no charge on the SEC's website: www.sec.gov. OCATA'S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT OFFER DOCUMENTS FILED WITH THE SEC BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. Logo - photos.prnewswire.com/prnh/20140416/84970 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-extends-tender-offer-to-acquire-all-outstanding-shares-of-ocata-therapeutics-300208419.html SOURCE Astellas Pharma Inc. Top of page
|
|
|
|
Post by JHam on Jan 22, 2016 15:15:00 GMT
Merged the above to this thread where there is already ongoing discussion. Thanks!
JHam
|
|
|
|
Post by harleyquinn on Jan 22, 2016 15:15:44 GMT
Agree with others here that this is essentially a done deal now, I wonder why the drop back to the 8.30s after the lift this AM.
|
|
|
|
Post by goldencoin9999 on Jan 22, 2016 15:28:59 GMT
They are not going to walk. Don't tender and make them pay.
|
|
|
|
Post by goldencoin9999 on Jan 22, 2016 15:56:03 GMT
If both Gary and Mario tendered then they will not get the remaining 3% this third round.
|
|
|
|
Post by harlem on Jan 22, 2016 17:02:41 GMT
Perhaps we were sold out cheap but what also comes to mind is that mgt has lied about EVERYTHING -- which may include the results, cost to move forward, etc. Like it or not, the only thing I can believe is that there is an offer of 8.50 on the table and the thought that the current mgt team might be in control for a while if astellas walks would be a nightmare. done deal imo glta and I do hope that mgt gets a dose of hell on earth.
|
|
|
|
Post by elk on Jan 22, 2016 20:08:07 GMT
SEC file out: On January 22, 2016, Purchaser extended the expiration of the Offer. The Offer was previously scheduled to expire at 5:00 p.m., New York City Time, on January 21, 2016. The Expiration Date of the Offer is extended to 5:00 p.m., New York City Time, on February 9, 2016, unless further extended. The Depositary has advised us that, as of 5:00 p.m., New York City time, on January 21, 2016, 19,862,037 Shares had been validly tendered and not validly withdrawn, representing approximately 47% of the outstanding Shares. ir.ocata.com/sec-filings/content/0001193125-16-435069/d128218dsctota.htm?TB_iframe=true&height=auto&width=auto&preload=falseWhere and what is the Depositary and who certifies its claim that 47% of shares having been tendered? |
|
|
|
Post by vzveteran on Jan 22, 2016 20:18:22 GMT
|
|
|
|
Post by vzveteran on Jan 22, 2016 20:28:20 GMT
Remember, and pass it on to the other boards, as I understand it, that you MUST exercise your appraisal rights, OR your shares will disappear from your account and be replaced with $8.50 cash per share held, should you refuse to tender and the merger completes.
|
|
|
|
Post by harlem on Jan 22, 2016 20:33:13 GMT
The article states Dec as the time frame Gary made his statement. He may or may not be in now. I believe He (and those who have appraisal rights) will also have the option to make a deal with Asstellas after the deal closes to sell shares/appraisal rights to Asstellas. A deal can be made with some or all of those with rights, giving Gary the ability to cut his own deal. glta
|
|
|
|
Post by imz72 on Jan 22, 2016 20:34:36 GMT
|
|
|
|
Post by vzveteran on Jan 22, 2016 20:40:44 GMT
The article states Dec as the time frame Gary made his statement. He may or may not be in now. I believe He (and those who have appraisal rights) will also have the option to make a deal with Asstellas after the deal closes to sell shares/appraisal rights if Asstellas makes an offer. The offer can be made to some or all of those with rights giving Gary the ability to cut his own deal. Right................ after the deal closes, you can "Settle out of court" with Astellas for your Dissenting shares.., until then any raise floats all shares. I have exercised appraisal rights for all mine. Should you do nothing, as I am hearing on the other board "I'm not Tendering" or "They will take them from my cold dead hands" is not good enough because should the deal complete, your shares are then cancelled and cash will be deposited in your account......... You need to be proactive in your DD here.... Just saying, ......I'm not recommending anything to anybody. |
|
|
|
Post by vzveteran on Jan 22, 2016 21:47:22 GMT
There's a lot of incomplete and misinformation being posted elsewhere.
Please call your broker, and or attorney for answers.
|
|
|
|
Post by icellman on Jan 23, 2016 3:35:25 GMT
How do we have proof that the 47% is a good number? I for one don't trust that number. I find it hard to believe they gained an additional 15% since the last deadline. Call me cynical, but I don't trust the whole process. It has a funny smell if you ask me. Why would anyone tender when they saw only 32 % had tendered prior. Anyone with common sense would have thought to hold to see if they could get a higher offer - correct? It just doesn't make sense.
|
|
|
|
Post by imz72 on Jan 23, 2016 7:38:58 GMT
How do we have proof that the 47% is a good number? I for one don't trust that number. I find it hard to believe they gained an additional 15% since the last deadline. Call me cynical, but I don't trust the whole process. It has a funny smell if you ask me. Why would anyone tender when they saw only 32 % had tendered prior. Anyone with common sense would have thought to hold to see if they could get a higher offer - correct? It just doesn't make sense. Sell, buy, hold or tender - every option makes sense. When you bought ACTC/OCAT shares you thought it makes sense, while other person/entity thought it makes sense selling them to you. And correction: The percentage of shares that were tendered in the first round was 36.21%. |
|
|
|
Post by goldencoin9999 on Jan 23, 2016 16:17:07 GMT
How do we have proof that the 47% is a good number? I for one don't trust that number. I find it hard to believe they gained an additional 15% since the last deadline. Call me cynical, but I don't trust the whole process. It has a funny smell if you ask me. Why would anyone tender when they saw only 32 % had tendered prior. Anyone with common sense would have thought to hold to see if they could get a higher offer - correct? It just doesn't make sense. Sell, buy, hold or tender - every option makes sense. When you bought ACTC/OCAT shares you thought it makes sense, while other person/entity thought it makes sense selling them to you. And correction: The percentage of shares that were tendered in the first round was 36.21%. What makes sense is the majority shareholders have voted NO two times. The crooks are still trying to force this deal down our throats and using every dirty tricks they could. |
|
|
|
Post by harlem on Jan 23, 2016 17:29:37 GMT
The crooks are the COB, BOD and c level mgt who accepted the deal on behalf of us all and stand to make millions of dollars for screwing many shareholders who believed that p2 would start in 2015 and according to PW interim results and inflection points would follow. Asstellas mgt looked at Ocata and decided that instead of buying a piece of a jv pie they could buy the bakery for peanuts from an incompetent and self-serving mgt team that told the investment bankers to ignore some of the IP. IMO mgt did NOT do their jobs in 2015 and instead spent their time lining their pockets with shares and misleading the shareholders. I hope that the lawsuits include going after mgt as individuals. I want to see PW told by a judge that this is NOT one of his conf calls and he must answer the questions. glta
|
|
|
|
Post by vzveteran on Jan 24, 2016 3:40:05 GMT
Drfeelgood is now a troll and banned from the other board.
He should have never spoken Ill of Obama.
If anyone can let him know, he's welcome here, as he said nothing particularly nasty.
|
|
asusdelux
Junior Member
UP listed.. now what?
Posts: 66
|
Post by asusdelux on Jan 24, 2016 13:33:04 GMT
How do we have proof that the 47% is a good number? I for one don't trust that number. I find it hard to believe they gained an additional 15% since the last deadline. Call me cynical, but I don't trust the whole process. It has a funny smell if you ask me. Why would anyone tender when they saw only 32 % had tendered prior. Anyone with common sense would have thought to hold to see if they could get a higher offer - correct? It just doesn't make sense. Sell, buy, hold or tender - every option makes sense. When you bought ACTC/OCAT shares you thought it makes sense, while other person/entity thought it makes sense selling them to you.And correction: The percentage of shares that were tendered in the first round was 36.21%. The underlined statement assumes all MM's are legit and that NO failures to deliver exist right? |
|
